Enhanced Compositions and Methods for the Treatment of Lowe Syndrome

The present inventive concept relates to improved RhoA inhibitors, statins, and mTOR inhibitors, and their combinations, for the treatment of Lowe Syndrome, providing enhanced efficacy, safety, and personalized treatment options.

Lowe Syndrome is a devastating genetic disease caused by mutations in the OCRL1 gene on the X chromosome. The original patent disclosed compositions and methods for treating Lowe Syndrome using RhoA inhibitors, statins, and mTOR inhibitors. However, the original patent has limitations, such as suboptimal dosing and lack of personalized treatment options. The present inventive concept addresses these limitations by introducing spatial regulation inhibitors, prenylation inhibitors, and systems for optimizing dosage and monitoring patient response.

The present inventive concept comprises a system for treating Lowe Syndrome, which includes a RhoA inhibitor and a mTOR inhibitor. The RhoA inhibitor is a spatial regulation inhibitor, and the mTOR inhibitor is rapamycin. The system is configured to optimize the dosage of the RhoA inhibitor based on the patient's response to the treatment. Additionally, the inventive concept includes a method for enhancing the efficacy of a Lowe Syndrome treatment by administering a combination of a statin and a mTOR inhibitor, and monitoring the patient's response to the treatment to adjust the dosage of the statin accordingly. The inventive concept also includes a pharmaceutical composition for the treatment of Lowe Syndrome, comprising a RhoA inhibitor, a mTOR inhibitor, and a pharmaceutically acceptable carrier, wherein the RhoA inhibitor is a prenylation inhibitor and the mTOR inhibitor is rapamycin, and the composition is formulated for oral administration.

The present inventive concept is novel and non-obvious compared to the original patent, as it introduces new and improved compositions and methods for treating Lowe Syndrome, including spatial regulation inhibitors, prenylation inhibitors, and systems for optimizing dosage and monitoring patient response. The inventive concept's novelty lies in its ability to provide enhanced efficacy, safety, and personalized treatment options for Lowe Syndrome patients.

Alternative embodiments of the inventive concept may include different types of RhoA inhibitors, such as farnesyltransferase inhibitors or geranylgeranyltransferase inhibitors, or different types of mTOR inhibitors, such as temsirolimus or everolimus. Additionally, the inventive concept may be implemented using different formulations, such as injectable or topical formulations, or different routes of administration, such as intravenous or oral administration.

The present inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of rare genetic diseases. The market for Lowe Syndrome treatments is expected to grow as the prevalence of the disease increases, and the inventive concept's ability to provide enhanced efficacy, safety, and personalized treatment options makes it an attractive solution for patients and healthcare providers.